
    
      This experiment adopts the method of multicenter, open, dose escalation study injection with
      recombinant human blood clean protein/granulocyte stimulating factor fusion protein after
      single and multiple doses of tolerance, security, and pharmacokinetic characteristics.

      Breast cancer patients with reduced white blood cells after chemotherapy were selected as
      subjects of this study.

      The three research doses that were to be incremented were 1.8 mg, 2.1mg and 2.4mg
      respectively, each of which was studied by single and multiple doses.

      Single dose of medicine, dose-climbing study.Two doses of the drug, dose-climbing study
    
  